Join to View Full Profile
207 S Santa Anita StSuite P-05San Gabriel, CA 91776
Dr. Yeh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Howard Yeh, MD, is an oncologist located in San Gabriel, CA, specializing in hematologic oncology. He completed his fellowship in hematology and medical oncology at the University of Texas Health Science Center at Houston/M D Anderson Cancer Center. Dr. Yeh has expertise in conditions such as amyloidosis, myelodysplasia, myelofibrosis, and multiple myeloma. Currently employed at The Oncology Institute of Hope & Innovation since 2022, he has authored multiple publications, including studies on denosumab versus zoledronic acid, which have been cited in other works. His research has contributed to supportive care in cancer and oncology fields.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1996 - 1999
SUNY Upstate Medical UniversityClass of 1996
Certifications & Licensure
CA State Medical License 2001 - 2027
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 87 citationsPhase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myelomaTorben Plesner, Hendrik-Tobias Arkenau, Peter Gimsing, Jakub Krejcik, Charlotte Lemech
Blood. 2016-10-06 - 2 citationsAbiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II brid...Cheol Kwak, Tony Tong Lin Wu, Hyun Moo Lee, Hsi Chin Wu, Sung Joon Hong
International Journal of Urology. 2014-12-01 - 122 citationsDelaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients ...David H. Henry, Saroj Vadhan-Raj, Vera Hirsh, Roger von Moos, Vania Hungria
Supportive Care in Cancer. 2014-03-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
